PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

'Path to 2025' Alzheimer's Disease Summit: Reforms urgently needed to streamline road to Alzheimer's

New report provides specific recommendations for governments, academia, and industry to reduce costs and increase efficiency in Alzheimer's R&D so new drugs reach patients faster and health systems save billions

2013-11-06
(Press-News.org) Contact information: Diana Friedman
dfriedman@nyas.org
212-298-8645
New York Academy of Sciences
'Path to 2025' Alzheimer's Disease Summit: Reforms urgently needed to streamline road to Alzheimer's New report provides specific recommendations for governments, academia, and industry to reduce costs and increase efficiency in Alzheimer's R&D so new drugs reach patients faster and health systems save billions NEW YORK, November 6, 2013 – As the burden of Alzheimer's disease escalates worldwide, efforts to develop effective treatments are failing to keep pace because of the high costs and risks associated with developing Alzheimer's drugs. Reforming Alzheimer's drug development, so it is more streamlined and efficient, would bring down costs and speed progress toward approval of drugs that slow or stop the disease. By meeting the U.S. goal of effective Alzheimer's prevention and treatment by 2025, millions of lives can be saved and improved, and billions of dollars in healthcare expenditures will be averted.

These are conclusions of a report on Alzheimer's drug development that will be discussed today at the "Alzheimer's Disease Summit: The Path to 2025" held at the New York Academy of Sciences (the Academy). The Summit, co-convened by the Academy, the Global CEO Initiative on Alzheimer's Disease (CEOi) and the U.S. National Institute on Aging/National Institutes of Health (NIH), brings together global leaders from government, academia, non-governmental organizations, and industry to accelerate progress on Alzheimer's research and development over the next decade. This Summit follows on the first Alzheimer's Disease Research Summit convened by the NIH in 2012.

"The Path to 2025" Summit comes during a pivotal time for Alzheimer's disease, as the requisite conditions for drug development success – from finance, business, science, and government – are converging, creating worldwide momentum in the fight against Alzheimer's. Helping drive this momentum, the new report, "Economic Analysis of Opportunities to Accelerate Alzheimer's Research and Development," available at http://www.nyas.org/Pathto2025report and commissioned by the Academy from RTI International, is presented today as a working draft to elicit comments and evaluation by the Alzheimer's experts at the Summit. A final version of the report will be published in Annals of the New York Academy of Sciences in early 2014, and is intended to serve as a further stimulus for action among stakeholders in the Alzheimer's field.

As the report draft delineates, rapid action is sorely needed. "Alzheimer's disease is a global emergency. It robs people of dignity in their final years and takes a debilitating toll on national economies," says New York Academy of Sciences President and CEO Ellis Rubinstein. "Progress in developing new therapies has been unacceptably slow, and so we must rethink how Alzheimer's research is carried out so that we can accelerate our understanding of what causes this complex disease."

"Global leadership and collaboration across business and government are essential to drive coordinated action, promote rapid innovation, and spur the focus needed to achieve a means of prevention and effective diagnosis, treatment, and care for Alzheimer's and dementia," says George Vradenburg, Convener of the CEOi. "The inefficiencies in the current drug development system can be addressed and we can meet the goal of stopping Alzheimer's by 2025."

Alzheimer's disease and other dementias currently affect more than 35 million people worldwide, with 2010 global expenditures alone reaching more than US $600 billion. The burden of Alzheimer's disease is projected to rise steeply as the number of people living with it roughly doubles by 2035, and triples by 2060, because of aging populations worldwide. Despite numerous large-scale drug trials, a treatment to slow or stop the progression of Alzheimer's has thus far proven elusive, and current therapies treat symptoms in limited populations for short periods of time. Recognizing the global implications of this crisis, the G8 is preparing for its first-ever meeting on dementia in London in December 2013.

Cost of Alzheimer's Drug Development Currently Three Times Industry Average One of the significant findings in the report is that the major bottlenecks in identifying an effective Alzheimer's disease treatment are the high cost and risk of drug development and research, particularly large clinical trials of thousands of patients over multiple years that test a single drug. The report estimates that the total cost of bringing an effective Alzheimer's treatment to market currently approaches $6 billion – nearly three times the industry average for drug development. (Total cost includes expenditures on an effective drug and on the failed drugs preceding it.)

The report considers the likely economic impacts of adopting a series of recommendations made by government agencies, expert panels, and other bodies to streamline how Alzheimer's drugs are developed and tested. Among the reforms recommended are:

Developing reliable disease markers to predict the progression of Alzheimer's disease in different patients and better match people with treatments likely to work for them;

Making clinical trials more efficient and less costly by establishing global trial-ready cohorts of eligible clinical trial participants as well as using adaptive trial designs that will enable the testing of multiple drugs, in combination, tailored for different at-risk populations;

Establishing data-sharing arrangements for companies to share precompetitive research results so that other scientists can learn more rapidly how to slow or stop Alzheimer's; and

Promoting public-private partnerships that pool resources from governments, academia, industry, and patient advocates to co-invest in Alzheimer's drug development and testing.

The report estimates that implementing these and other reforms to Alzheimer's drug development would reduce the total cost of developing an effective Alzheimer's treatment by nearly $4 billion and reduce significantly the overall timeline to develop and introduce a successful Alzheimer's treatment, bringing both more in line with the industry average. The recommended reforms would also lead to increased private investment in Alzheimer's drug development.

Speeding the availability of an Alzheimer's drug that can slow or stop the disease by 2025 could have tremendous benefit for patients and health systems. By creating conditions favorable to Alzheimer's drug development through targeted recommendations, 7 million case-years of dementia could be averted and upwards of $100 billion in healthcare expenditures could be saved over a 15-year period in the United States alone, according to the Academy-commissioned report.

'The Path to 2025' Summit Convenes Global Alzheimer's Leaders to Address Research Bottlenecks "The Path to 2025" Summit of November 6-7, 2013, begins a new biannual meeting intended to identify the actions needed to achieve the goal of preventing and effectively treating Alzheimer's disease by 2025, including the identification of additional public and private resources; the execution of field-wide priorities dedicated to Alzheimer's research and development; and adoption of the reforms recommended in the RTI report. This Summit is intended to alternate with the biannual Alzheimer's Disease Summits convened by the U.S. National Institutes of Health. "The Path to 2025" is a project of the New York Academy of Sciences, the Global CEO Initiative on Alzheimer's Disease, and the National Institute on Aging/NIH. The Academy, working through its Alzheimer's Disease and Dementia Initiative, has prioritized Alzheimer's disease because of the inherent societal and economic challenges, and the opportunity to advance science and deliver transformative solutions for those with and at risk for Alzheimer's disease.

Presentations and discussions at "The Path to 2025" focus on ways for public and private sector organizations, including those in the biopharmaceutical, academic, government, technology, financial services, healthcare delivery, philanthropic, and patient advocacy communities, to collaborate more strategically and efficiently on Alzheimer's research and drug development goals. For more information on the Summit, including the agenda and speaker biographies, visit http://www.nyas.org/Pathto2025.

### About the New York Academy of Sciences The New York Academy of Sciences is an independent, not-for-profit organization that since 1817 has been committed to advancing science, technology and society worldwide. With 25,000 members in 140 countries, the Academy is creating a global community of science for the benefit of humanity. The Academy's core mission is to advance scientific knowledge, positively impact the major global challenges of society with science-based solutions, and increase the number of scientifically informed individuals in society at large. Please visit us online at http://www.nyas.org.

About the Global CEO Initiative on Alzheimer's Disease The Global CEO Initiative on Alzheimer's Disease represents an acceptance of the invitation from public authorities, domestically and internationally, to the private sector to forge robust public-private partnerships to stop Alzheimer's disease and dementia. Our vision is that the CEO Initiative becomes a leading business voice on this seminal public health issue of our time, which will have profound impact in fiscal, social and political matters as we "change the game" on Alzheimer's. By working together and in partnership with leading non-governmental organizations and governments, the CEO Initiative will identify and pursue research, therapy development, financing and public awareness projects of the highest priority that, when achieved, can transform the global fight to stop Alzheimer's disease. Please visit http://www.ceoalzheimersinitiative.org.


ELSE PRESS RELEASES FROM THIS DATE:

Prognostic value of baseline HRQOL for survival for 11 types of cancer pointed out by EORTC study

2013-11-06
Prognostic value of baseline HRQOL for survival for 11 types of cancer pointed out by EORTC study Results of an EORTC study published in Cancer point out the prognostic value of baseline recorded health-related quality of life for survival for ...

Nature's great diversity: Remarkable 277 new wasp species from Costa Rica

2013-11-06
Nature's great diversity: Remarkable 277 new wasp species from Costa Rica Costa Rica reveals astonishing biodiversity of braconid wasps, with 277 new species of the tribe Heterospilini described in the latest special issue of the open access journal ZooKeys. This is the second ...

Touch may alleviate existential fears for people with low self-esteem

2013-11-06
Touch may alleviate existential fears for people with low self-esteem As human beings, we all know that we are going to die some day. Most of us deal with this knowledge by trying to live meaningful lives, but people with low self-esteem ...

NIST's new compact atomic clock design uses cold atoms to boost precision

2013-11-06
NIST's new compact atomic clock design uses cold atoms to boost precision Physicists at the National Institute of Standards and Technology (NIST) have demonstrated a compact atomic clock design that relies on cold rubidium atoms instead ...

Cocktail novelties inspired by nature's designs

2013-11-06
Cocktail novelties inspired by nature's designs Mechanisms behind water bugs and lilies applied to culinary devices CAMBRIDGE, MA -- An MIT mathematician and a celebrity chef have combined talents to create two culinary novelties inspired by nature. John ...

Perfect faults: A self-correcting crystal may unleash the next generation of advanced communications

2013-11-06
Perfect faults: A self-correcting crystal may unleash the next generation of advanced communications Researchers from the National Institute of Standards and Technology (NIST) have joined with an international team to engineer and ...

Recent National Science Foundation study reveals increase in state government expenditures for research and development

2013-11-06
Recent National Science Foundation study reveals increase in state government expenditures for research and development According to a recent study published by the National Science Foundation (NSF), state government agency expenditures for research and development ...

Updating building energy codes: How much can your state save?

2013-11-06
Updating building energy codes: How much can your state save? How much in energy and cost savings would your state realize if it updated its commercial building energy codes? You can find out in a new on-line publication* from the National ...

Not just a pretty face: Bodies provide important cues for recognizing people

2013-11-06
Not just a pretty face: Bodies provide important cues for recognizing people Computer recognition of people has focused almost exclusively on faces, but a new study suggests it may be time to take additional information into consideration. ...

Postoperative pain may increase risk of temporary problems with learning, memory

2013-11-06
Postoperative pain may increase risk of temporary problems with learning, memory The pain caused by a surgical incision may contribute to the risk of postoperative cognitive dysfunction, a sometimes transient impairment in learning and memory that affects ...

LAST 30 PRESS RELEASES:

Global South cities hold key to unlocking healthcare solutions – studies show

Autism not linked with increased age-related cognitive decline

Study shows 90% metal pollution drop in Adirondack waters five decades after the clean air act

Can technology revolutionize health science? The promise of exposomics

Human pressure most affecting Atlantic Rainforest deer density, study finds

The effects of smoking, drinking and lack of exercise are felt by the age of 36, new research indicates

Nanophotonic platform boosts efficiency of nonlinear-optical quantum teleportation

Scientists urge plastic limit for lateral flow tests

Prepare today to save lives tomorrow: SFU study finds gaps in B.C. extreme heat response plans

National Foundation for Cancer Research congratulates Dr. Rakesh Jain on AACR Lifetime Achievement Award

Farms with more intensive management have lower soil functionality

Tracing the emergence and spread of H5N1 in U.S dairy cattle

Carnivorous “bone collector” caterpillar patrols spiderwebs while adorned in body parts of its insect prey

New approach to silicone waste recycling closes the loop

Blocking a surprising master regulator of immunity eradicates liver tumors in mice

A new recycling process for silicones could greatly reduce the sector’s environmental impacts

Simple consultations in emergency room can help patients manage high blood pressure

Metachromatic Leukodystrophy (MLD) and gene therapy: a game-changing treatment backed by NEJM—Timing Is Everything

Estimating complex immune cell structures by AI tools for survival prediction in advanced melanoma

Modeling reemergence of vaccine-eliminated infectious diseases under declining vaccination in the US

2024 Top 100 US Universities announced by the National Academy of Inventors

Female bonobos keep males in check—not with strength, but with solidarity

What happens in the brain when your mind blanks

The oldest ant ever discovered found fossilized in Brazil

Health care cost concerns and hardships for families of children with disabilities

Trends in mental health diagnoses among publicly insured children

Measles may be making a comeback in the US, Stanford Medicine-led research finds

We still have a representation problem for women in physics – and Canada is no exception

Even light exercise could help slow cognitive decline in people at risk of Alzheimer’s

Prostate cancer discovery opens door to more tailored treatments

[Press-News.org] 'Path to 2025' Alzheimer's Disease Summit: Reforms urgently needed to streamline road to Alzheimer's
New report provides specific recommendations for governments, academia, and industry to reduce costs and increase efficiency in Alzheimer's R&D so new drugs reach patients faster and health systems save billions